BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16773846)

  • 1. Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
    Sandler AB
    Oncology (Williston Park); 2006 May; 20(6):626-8. PubMed ID: 16773846
    [No Abstract]   [Full Text] [Related]  

  • 2. Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
    Liu D; Yang Y; Zhao S
    J Formos Med Assoc; 2014 Mar; 113(3):141-2. PubMed ID: 24630031
    [No Abstract]   [Full Text] [Related]  

  • 3. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 4. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
    Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
    [No Abstract]   [Full Text] [Related]  

  • 5. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 6. [New era in cancer therapy. Gefitinib: small molecule--strong action].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
    [No Abstract]   [Full Text] [Related]  

  • 7. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
    Garfield DH
    J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
    [No Abstract]   [Full Text] [Related]  

  • 8. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 9. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 10. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictive biomarkers for EGFR therapy.
    Sakurada A; Tsao MS
    IDrugs; 2009 Jan; 12(1):34-8. PubMed ID: 19127503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in lung cancer: a tribute to advancements in clinical research.
    McGee L
    ONS Connect; 2007; 22(8 Suppl):27-8. PubMed ID: 17824552
    [No Abstract]   [Full Text] [Related]  

  • 13. First-line erlotinib inferior to chemo in advanced lung cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):930-1. PubMed ID: 23176004
    [No Abstract]   [Full Text] [Related]  

  • 14. Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Myerson JS; Iqbal SA; O'Brien ME; Popat S
    Clin Lung Cancer; 2010 Sep; 11(5):E5-8. PubMed ID: 20837451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
    Kotsakis A; Georgoulias V
    Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
    Kim DW; Choy H
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will lung cancer targeting hit its mark?
    Hampton T
    JAMA; 2005 Apr; 293(16):1963-4. PubMed ID: 15855415
    [No Abstract]   [Full Text] [Related]  

  • 19. EGFR inhibition in NSCLC: the emerging role of cetuximab.
    Herbst RS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.